Quality of life ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Live birth · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin may leads to higher live birth compared with aspirin (low certainty).
1 finding from 1 review
Pre‐eclampsia · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin showed no clear difference in pre‐eclampsia compared with aspirin (low certainty).
1 finding from 1 review
Adverse events in the mother ‐ Bleeding · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin showed no clear difference in adverse events in the mother ‐ Bleeding compared with aspirin (low certainty).
1 finding from 1 review
Allergic reaction · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Venous thromboembolism · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Arterial thromboembolism · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Pregnancy loss · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin may leads to lower pregnancy loss compared with aspirin (low certainty).
1 finding from 1 review
Preterm delivery of a live infant · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether heparin plus aspirin changes preterm delivery of a live infant compared with aspirin (very low certainty).
1 finding from 1 review
Intrauterine growth restriction · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether heparin plus aspirin changes intrauterine growth restriction compared with aspirin (very low certainty).
1 finding from 1 review
Adverse events in the child ‐ Congenital malformations · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
Combined NMES and low‐dose heparin may leads to lower total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review